Healthcare / BiotechnologyNasdaqGM
$0.76
-0.01 (-1.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-26.8M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$27M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-279.3%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-55.9M · FCF $-43.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Net Income | $-55.9M | $-55.9M | $-26.6M | $-37.6M | $-19.5M | $-8.5M | $-6.6M | $1.1M | $-19.2M | $-3.1M | $-3.2M | $-4.8M | $-2.7M | $-120403.00 | $4509.00 |
| EBITDA | $-55.2M | $-55.2M | $-25.3M | $-36.6M | $-18.7M | — | — | — | — | — | — | — | — | — | — |
| EPS | -1.41 | -1.41 | -0.73 | -5.37 | -8.77 | -5.00 | -7.50 | -12.50 | -40.00 | -27.50 | -42.50 | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | -2.16 | -0.66 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.78 | 1.78 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-43.1M | $-43.1M | $-26.8M | $-14.0M | $-12.8M | $-6.6M | $-6.1M | — | $-3.9M | $-3.4M | — | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -279.3% | -279.3% | -39.0% | 1765.9% | 647.6% | -145.3% | -1455.4% | 191.9% | 123.3% | 86.7% | 109.1% | 542.6% | 602.8% | 66.1% | 11.7% |
| Valuation | |||||||||||||||
| P/B | 1.51 | 1.51 | 1.53 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | -93.2% | -93.2% | 86.4% | 38.8% | — | 33.3% | 40.0% | 68.8% | -45.5% | 35.3% | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.73 → -1.41
Residual
-61.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.